Dong-A ST has received the right of MerTK inhibitor from AbbVie for the first time in five years. Dong-A ST has terminated two large technology export contracts with global pharmaceutical companies.

Dong-A ST plans to review new possibilities based on joint research data that has been conducted for the past five years. Starting with biosimilar for Stelara, it is seeking new growth engines by combining its own pipeline R&D and active open innovation strategies such as diabetes and dementia.
◆AbbVie, returning rights to new drugs in five years "Not meeting internal standards"

Dong-A ST announced on the 9th that it had been notified by AbbVie that it had returned the rights of